Rani Therapeutics secured Series C funding

What does Rani Therapeutics do?

Rani Therapeutics, is a startup which develops bio-therapeutics technology for oral delivery of large drug molecules which includes antibodies, peptides and proteins. It is currently in pre-clinical studies and has demonstrated more than 50% bioavailability. It is also currently exploring partnerships with pharmaceutical companies. Its investors currently include Google Ventures, Venture Health and InCube Ventures. Rani therapeutics approach and technology was developed at InCube Lanbs, which is a multi-disciplinary life sciences research and development lab which is focused on developing breakthrough medical innovations.

How much Rani Therapeutics was funded?

Rani Therapeutics raised an undisclosed amount in Series C funding on May 26, 2015 from Pacific Venture Opportunity Fund, Crystal Horizon Investments, Pinemount Investment, VentureHealth, The Stevanato Group , Western Life Sciences Venture Fund LP and other angel investors.

Previous funding

• An undisclosed amount in Series B funding on August 28, 2013 from InCube Ventures and Google Ventures.

What is next for Rani Therapeutics?

With the latest funding, the bio-therapeutics company will help it continue to de-risk its platform and create the manufacturing infrastructure necessary for its clinical trials and much more. The company is committed to delivering on its promise to transform radically how the biological drugs are delivered to patients. The latest investment is an important step forward for the company.

The company has also recently announced a collaboration partnership with Novartis, which includes feasibility studies to evaluate how the company’s selected proprietary biologics are delivers into the blood using its unique route of administration.

More about Rani Therapeutics

Rani Therapeutics was founded by Mir Imran. It has its headquarters in San Jose, CA. It has developed a technology platform for converting injectable drugs like interleukin antibodies, TNF- alpha Inhibitors and basal insulin among others into pills. It has begun developing partnerships with pharmacy companies for testing its platform with select drugs.